Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDURA vs GLYSET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective antagonist of alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and prostate.
Competitive inhibitor of alpha-glucosidase enzymes in the small intestine, delaying the breakdown of complex carbohydrates into monosaccharides and reducing postprandial hyperglycemia.
Hypertension,Benign prostatic hyperplasia
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Initial: 1 mg orally once daily, titrated based on standing blood pressure response up to 16 mg daily as a single dose or divided twice daily. Maximum: 16 mg/day.
50 mg orally three times daily, titrated to 100 mg three times daily as tolerated, taken at the start of each meal.
Terminal elimination half-life is approximately 22 hours, allowing once-daily dosing; peak effect on blood pressure occurs at 2-6 hours post-dose.
Terminal elimination half-life is approximately 2-3 hours in patients with normal renal function (creatinine clearance >60 m L/min). Clinical context: No accumulation occurs with twice-daily dosing in normal renal function; half-life is prolonged in renal impairment (up to 18 hours in end-stage renal disease).
Extensively metabolized in the liver via O-demethylation and hydroxylation; CYP3A4 is the major enzyme involved.
Not metabolized; excreted unchanged primarily in feces (51% as unchanged drug, 35% as metabolites) and urine (2-5% as unchanged drug).
Primarily hepatic metabolism (approx. 60-70%) with biliary excretion of metabolites; renal excretion accounts for about 30-40% of the dose, mainly as metabolites with <5% unchanged drug.
Primarily excreted unchanged in the urine (renal elimination accounts for >95% of absorbed dose). Fecal elimination is negligible (<2%).
98-99% bound to plasma proteins (primarily albumin).
Protein binding is very low (approximately 5-10%), primarily to albumin, with no significant binding to other plasma proteins.
0.5-1.0 L/kg (approximately 50-70 L in adults); indicates extensive extravascular distribution.
Volume of distribution is approximately 0.3-0.5 L/kg, indicating distribution mainly in extracellular fluid and minimal tissue binding.
Oral bioavailability is approximately 65% (range 43-81%) with minimal first-pass effect.
Oral bioavailability is <2% for the parent compound due to extensive metabolism by intestinal bacteria; however, the active metabolite (miglitol-like) has high local activity. Systemic absorption is minimal (1-2%), consistent with its site of action in the gut.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, start with 0.5 mg daily and titrate cautiously due to increased sensitivity.
Contraindicated if GFR < 25 m L/min/1.73 m². No adjustment needed for GFR ≥ 25 m L/min/1.73 m².
Child-Pugh A: Start at 0.5 mg daily. Child-Pugh B or C: Contraindicated due to extensive hepatic metabolism.
No specific guidelines; use caution in Child-Pugh class B or C due to limited data.
Safety and efficacy not established in pediatric patients; use not recommended.
Not recommended for pediatric patients due to lack of safety and efficacy data.
Initiate at 0.5 mg daily due to increased risk of orthostatic hypotension. Titrate slowly based on tolerability and response.
Initiate at lowest dose (50 mg three times daily); titrate cautiously due to age-related renal decline.
None
None
Orthostatic hypotension and syncope, especially with first dose,Use with caution in patients with hepatic impairment,Risk of priapism,Intraoperative floppy iris syndrome during cataract surgery
Hypoglycemia when used in combination with sulfonylureas or insulin (must be treated with glucose, not sucrose),Gastrointestinal adverse effects (abdominal pain, diarrhea, flatulence) due to undigested carbohydrates fermenting in the colon,Hepatotoxicity (rare, monitor liver enzymes),May cause loss of glycemic control if used with intestinal disorders
Hypersensitivity to doxazosin or other quinazolines
Diabetic ketoacidosis,Inflammatory bowel disease,Colonic ulceration,Partial intestinal obstruction,Predisposition to intestinal obstruction,Chronic intestinal diseases associated with marked disorders of digestion or absorption,Cirrhosis,Hypersensitivity to miglitol
Avoid grapefruit and grapefruit juice as they may increase doxazosin levels. Take with food to reduce gastrointestinal upset. No other significant food interactions.
Avoid high-sucrose or fructose-containing foods and drinks as GLYSET inhibits the digestion of sucrose, leading to increased fermentation and gastrointestinal distress. Complex carbohydrates (starches) are affected; simple sugars like glucose are not.
Pregnancy Category C. First trimester: No evidence of teratogenicity in animal studies; limited human data. Second/third trimesters: Potential risk of fetal hypotension and hypoxia from maternal hypotension. Avoid use in pregnancy unless benefit outweighs risk.
Pregnancy Category B. No evidence of fetal harm in animal studies; no adequate human studies in first trimester. Use only if clearly needed.
Excreted in human milk; M/P ratio unknown. Caution due to potential for hypotension in nursing infants. Use only if essential.
Excreted in human milk; M/P ratio unknown. Caution in nursing mothers due to potential for GI effects in infants.
No established dose adjustments for pregnancy; use lowest effective dose due to potential for increased clearance and changes in volume of distribution.
No dose adjustment recommended based on pharmacokinetic data; monitor glycemic control closely and adjust as needed.
CARDURA (doxazosin) is an alpha-1 blocker used for hypertension and benign prostatic hyperplasia (BPH). First-dose syncope is more common with immediate-release (IR) than extended-release (GITS). Start IR at 1 mg at bedtime and titrate slowly. GITS formulation minimizes orthostatic effects. Monitor blood pressure carefully in elderly patients. May cause intraoperative floppy iris syndrome (IFIS) during cataract surgery; do not stop therapy preoperatively. Avoid use in patients with orthostatic hypotension or micturition syncope.
GLYSET (miglitol) is an alpha-glucosidase inhibitor that delays carbohydrate digestion, reducing postprandial hyperglycemia. It is not effective for fasting hyperglycemia and should not be used as monotherapy for type 1 diabetes or DKA. Monitor liver function tests; rare hepatotoxicity reported. Avoid in patients with inflammatory bowel disease or intestinal obstruction.
Take the first dose at bedtime to minimize dizziness. Sit or lie down if you feel lightheaded.,Avoid sudden position changes; rise slowly from sitting or lying positions.,May cause dizziness, drowsiness, or blurred vision. Do not drive until you know how CARDURA affects you.,For BPH, it may take up to 2 weeks to improve symptoms. Do not stop medication abruptly.,Inform your surgeon if you are scheduled for cataract surgery; CARDURA may affect eye surgery outcomes.,Avoid alcohol, which can worsen side effects like dizziness and low blood pressure.,For hypertension, continue regular monitoring with your healthcare provider.
Take with the first bite of each main meal to delay carbohydrate absorption.,Common side effects include flatulence, diarrhea, and abdominal discomfort, which often improve over time.,If hypoglycemia occurs, use glucose tablets or milk, not sucrose or fruit juice, as GLYSET prevents sucrose breakdown.,Monitor blood glucose regularly, especially when starting or changing dose.,Do not skip meals; take medication exactly as prescribed.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDURA vs GLYSET, answered by our medical review team.
CARDURA is a Alpha-1 Blocker Antihypertensive that works by Selective antagonist of alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and prostate.. GLYSET is a Alpha-Glucosidase Inhibitor Antidiabetic that works by Competitive inhibitor of alpha-glucosidase enzymes in the small intestine, delaying the breakdown of complex carbohydrates into monosaccharides and reducing postprandial hyperglycemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDURA and GLYSET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDURA is: Initial: 1 mg orally once daily, titrated based on standing blood pressure response up to 16 mg daily as a single dose or divided twice daily. Maximum: 16 mg/day.. The standard adult dose of GLYSET is: 50 mg orally three times daily, titrated to 100 mg three times daily as tolerated, taken at the start of each meal.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDURA and GLYSET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDURA is classified as Category C. Pregnancy Category C. First trimester: No evidence of teratogenicity in animal studies; limited human data. Second/third trimesters: Potential risk of fetal hypotension and hypoxia. GLYSET is classified as Category C. Pregnancy Category B. No evidence of fetal harm in animal studies; no adequate human studies in first trimester. Use only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.